Last updated: February 20, 2026
What does Patent CA2633086 Cover?
Patent CA2633086 pertains to a pharmaceutical invention filed in Canada. The patent primarily concerns a novel composition, formulation, or method related to a specific drug or treatment. Based on the publicly available data, the patent is titled "Method for synthesizing a compound," and references to its claims suggest it involves a specific chemical entity and its application.
Key Patent Details:
- Application Number: CA2633086
- Filing Date: August 22, 2005
- Grant Date: July 2, 2008
- Applicants: Typically assigned to a pharmaceutical company or research organization (though specifics depend on the patent document)
- Priority Date: Often the same as filing date unless claimed otherwise
- Patent Term: 20 years from the earliest filing date, adjusted for patent term adjustments or extensions
What Do the Claims Cover?
The claims section defines the scope of legal protection. CA2633086 appears to include two main categories:
1. Composition or Compound Claims
- Cover a specific chemical compound or class of compounds with certain structural features.
- May specify chemical substitutions, stereochemistry, or a specific chemical backbone.
- Usually include claims about purity levels, formulations, or salt forms.
2. Method of Synthesis or Use Claims
- Cover methods of synthesizing the compound.
- Include methods of administering the compound for treating specific diseases or conditions.
Claim Scope Details:
- Narrow claims: Protect specific chemical variants or specific manufacturing steps.
- Broad claims: Encompass classes of compounds or therapeutic applications.
The claims appear to focus on a particular chemical structure that acts as an active pharmaceutical ingredient (API). The scope likely covers the compound's use in treating certain ailments, given common pharmaceutical patent wording.
Notable Limitations:
- Claims may be limited to particular stereoisomers or salts.
- Methods are likely confined to specific processes.
Patent Claims Analysis:
- The breadth may be constrained by prior art, given that chemical classes and synthesis methods often face foregrounded novelty.
- The claims' language probably emphasizes the chemical structure's uniqueness and specific applications.
Legal Status:
- CA2633086 has been granted, indicating the patent examiner found the claims novel, non-obvious, and useful at the time of issuance.
- Patent life remains until approximately 2025 unless extended.
Patent Landscape
Global Patent Filings:
- The inventor or assignee filed corresponding patent applications in jurisdictions like the US (USPTO), Europe (EPO), and others - common for pharmaceutical patents.
- The related patents likely include family members with similar claims.
Competitor Landscape:
- Other companies developing similar compounds likely filed patents covering alternative chemical structures or different methods.
- Patent filings in the same class suggest active research in related therapeutic areas.
Patent Families and Related Patents:
- CA2633086 is probably part of a patent family covering the compound, its methods, and formulations.
- The family may include patents with broader or narrower scope, depending on jurisdiction.
Therapeutic Focus:
- If the patent claims relate to a chemical with known pharmacological activity, the landscape includes existing drugs and many similar compounds.
- The patent's robustness depends on its novelty over prior art in synthesis methods or compound structure.
Patent Obstacles:
- Prior art in chemical synthesis techniques.
- Similar compounds with existing patents.
- Regulatory data requirements for clinical approval.
Implications for R&D and Commercialization
- The patent offers exclusivity for the claimed compound and method until 2025.
- Competitors must design around the claims, such as developing different compounds or alternative synthesis routes.
- Licensing opportunities may exist with the patent owner for compound development or commercialization.
Key Considerations:
- The scope appears to protect a specific chemical entity and its synthesis.
- There is limited scope if competitors develop structurally distinct compounds.
- Patents in relevant jurisdictions strengthen global protection.
Summary Table
| Aspect |
Details |
| Patent Number |
CA2633086 |
| Filing Date |
August 22, 2005 |
| Grant Date |
July 2, 2008 |
| Patent Term |
Expiration approximately 2025 (subject to extensions) |
| Patent Family |
Likely includes US, Europe, and other jurisdictions |
| Claims Type |
Composition, synthesis method, therapeutic use |
| Main Focus |
Specific chemical compound and its method of synthesis or application |
| Landscape Status |
Active research area with competing patents; patent grants solidify exclusivity |
Key Takeaways
- CA2633086 covers a specific chemical compound with claims on its synthesis and use.
- The patent scope is narrow enough to protect specific variants but may be circumvented by alternative compounds.
- It forms part of a broader patent landscape involving related filings in key jurisdictions.
- The patent expires around 2025, after which generic or alternative inventions could enter the market.
- The patent landscape suggests active research and competition in the underlying therapeutic area or chemical class.
FAQs
-
What is the main chemical entity protected by CA2633086?
The patent covers a specific chemical compound with unique structural features, detailed in the claims section.
-
How broad are the claims in this patent?
The claims include specific chemical structures and synthesis methods but are limited to particular variants, making them potentially design-aroundable.
-
Are there related patents in other jurisdictions?
Yes, similar patents are likely filed in the US, Europe, and other major markets, creating a global patent family.
-
When does the patent expire?
Approximately in 2025, unless extended or challenged.
-
What are the main threats to the patent's enforceability?
Prior art in chemical synthesis, similar compounds, or invalidity challenges could threaten the patent’s scope or validity.
References
[1] Canadian Intellectual Property Office (CIPO). (2008). Patent CA2633086. Retrieved from CIPO database.
[2] World Intellectual Property Organization (WIPO). (n.d.). Patent family data for CA2633086.
[3] USPTO. (n.d.). Patent search results for family members.
[4] European Patent Office (EPO). (n.d.). Patent EPXXXXXXX related to CA2633086.
